Viropro Stock Today
PerformanceWeakest
| Odds Of DistressRisky
|
Viropro has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 31st of October 2025 and ending today, the 29th of January 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Viropro Inc., through its subsidiaries, engages in the contract research, development, and manufacture of biotherapeutic proteins for the treatment of various diseases. Viropro Inc. has collaboration agreement with Oncobiologics, Inc. to manufacture and commercialize monoclonal antibody products. The company has 916.09 M outstanding shares. More on Viropro
Viropro cannot be verified against its exchange. It looks like Viropro is not available for investing at the moment. Please verify the symbol is currently traded on OTCCE Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
RefreshViropro Stock Highlights
| CEO | Michelle Peake |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Viropro (VPRO) is traded on OTCCE Exchange in USA and employs 3 people. Viropro is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 18.32 K. Viropro conducts business under Biotechnology sector and is part of Health Care industry. The entity has 916.09 M outstanding shares.
Viropro currently holds about 119.25 K in cash with (675.62 K) of positive cash flow from operations.
Check Viropro Probability Of Bankruptcy
Viropro Historical Income Statement
Viropro Stock Against Markets
Try Other Suggestions
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viropro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Viropro Stock, please use our How to Invest in Viropro guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Will Biotechnology sector continue expanding? Could Viropro diversify its offerings? Factors like these will boost the valuation of Viropro. If investors know Viropro will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Viropro data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Revenue Growth 1.19 |
Understanding Viropro requires distinguishing between market price and book value, where the latter reflects Viropro's accounting equity. The concept of intrinsic value—what Viropro's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Viropro's price substantially above or below its fundamental value.
Please note, there is a significant difference between Viropro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Viropro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Viropro's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.